Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK: Does new RSV jab have the edge of Pfizer's vaccine?
03:13am, Wednesday, 21'st Jun 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine, Arexvy, demonstrated robust long-term protection in a late-stage trial, targeting older adults, the pharma giant revealed on We
GSK's RSV vaccine shows long-term efficacy in late-stage trial
02:31am, Wednesday, 21'st Jun 2023
GSK on Wednesday said its vaccine for the respiratory syncytial virus (RSV), which recently won EU approval, showed strong long-term protection in older adults in a late-stage trial.
GSK vs. TECH: Which Stock Should Value Investors Buy Now?
01:16pm, Tuesday, 20'th Jun 2023
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either GSK (GSK) or Techne (TECH). But which of these two stocks presents investors with the better
GSK Announces Extension of FDA Review for Rare Blood Therapy
11:43am, Monday, 19'th Jun 2023
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
Bellus Health shareholders say yes to US$2B GSK takeover
10:04am, Monday, 19'th Jun 2023
BELLUS Health Inc (TSX:BLU) said its shareholders overwhelmingly have approved a US$2 billion takeover by GSK PLC (LSE:GSK, NYSE:GSK). The late-stage biopharmaceutical firm said in a statement that al
2 Top Healthcare Stocks to Buy Right Now
09:15am, Friday, 16'th Jun 2023
A growing and aging population bodes well for companies in the healthcare industry. GSK is a long-established drugmaker that is still innovating and developing promising products.
GSK delay for new drug with US regulator 'not necessarily a red flag' - analyst
08:11am, Friday, 16'th Jun 2023
A regulatory delay for GSK PLC (LSE:GSK, NYSE:GSK) with the 'centrepiece' drug of its US$2bn Sierra Oncology (NASDAQ:SRRA) acquisition last year "isn't necessarily a red flag", according to an anal
GSK says FDA extends review period for experimental drug momelotinib
02:29am, Friday, 16'th Jun 2023
British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a
GSK plc (GSK) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
03:35pm, Tuesday, 13'th Jun 2023
GSK plc (NYSE:GSK ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 12:20 PM ET Company Participants Tony Wood - Chief Scientific Officer Conference Call Participants Chris S
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
02:34pm, Wednesday, 07'th Jun 2023
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
June 2023 Stock Considerations
01:30am, Wednesday, 07'th Jun 2023
With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases. With the market still having a tough time in 2023 we see no shortages of stock
GSK's cancer drug Jemperli gets file acceptance from US FDA
02:59am, Tuesday, 06'th Jun 2023
GSK said on Tuesday that the U.S. Food and Drug Administration had granted file acceptance for its cancer drug, Jemperli, when combined with chemotherapy to treat adult patients with certain types of
Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating
04:57pm, Friday, 19'th May 2023
SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential lab
What To Expect From GSK In 2023
01:29am, Tuesday, 16'th May 2023
GSK's operating income margin in Q1 2023 was 29.35%, showing an increase in the previous quarter and the last year. Vaccine sales were $2,493 million in Q1 2023, up 11.9% year-over-year, mainly due to
GSK: So, just how big is the RSV opportunity? Up to $9bn, says one broker
11:11am, Monday, 15'th May 2023
Shore Capital has examined the prospects of GSK PLC (LSE:GSK, NYSE:GSK)'s newly approved respiratory syncytial virus (RSV) vaccine, Arexvy, and believes it could eventually be a blockbuster several ti
